✦ LIBER ✦

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

✍ Scribed by Zhao, Qiong; Shentu, Jianzhong; Xu, Nong; Zhou, Jianya; Yang, Guangdie; Yao, Yinan; Tan, Fenlai; Liu, Dongyang; Wang, Yingxiang; Zhou, Jianying

Book ID: 119320500
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 498 KB
Volume: 73
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2010.11.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

53LBA A phase I/IIa study of icotinib hy

53LBA A phase I/IIa study of icotinib hydrochloride (BPI-2009H), an oral epidermal growth factor receptor tyrosine kinases inhibitor, in patients with advanced non-small-cell lung cancer and other solid tumors

✍ Q. Zhao; J. Zhou; J. Shentu; L. Wu; N. Xu; F. Tan; Y. Wang; D. Yang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A phase I dose escalation study of epide

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Phase I and pharmacokinetic study of sor

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

✍ Hironobu Minami; Kenji Kawada; Hiromichi Ebi; Koichi Kitagawa; Yon-il Kim; Kazuh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Phase I–IIa study of BMS-690514, an EGFR

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

✍ Soria, Jean-Charles; Baselga, José; Hanna, Nasser; Laurie, Scott A.; Bahleda, Ra 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 343 KB

137 A phase I study of an oral vascular

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

✍ Tolcher, A.; O'Leary, J.J.; DeBono, J.; Molpus, K.; Woodard, C.; Warnat, M.; Lia 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Effects of ZD6474, an orally active inhi

Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study

✍ S. Holden; S. Eckhardt; R. Basser; D. Rischin; H. Hurwitz; R. DeBoer; M. Rosenth 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB